Selank Dosage Guide: Russian Clinical Evidence, Reconstitution and Safety

Selank is a synthetic heptapeptide developed in Russia as a tuftsin analogue and has been registered there since the 1990s as a nasal spray for anxiety disorders and neurasthenia. Published Russian clinical studies report anxiolytic effects comparable to benzodiazepines such as medazepam and phenazepam, without the sedation and dependence typically associated with that drug class, plus animal and cell-culture work describing effects on GABAergic gene expression and enkephalin-degrading enzymes. No Western randomized controlled trial has been published, and the FDA has not approved Selank for any use. The subcutaneous injection route common in research communities has not itself been tested in the published clinical literature.

The supplied source describes two separate protocol shapes: a subcutaneous schedule of 250–500 mcg once daily for 4 weeks followed by 4 weeks off (with some reports of 100–300 mcg being described elsewhere as well tolerated), and an intranasal schedule of 600–2,700 mcg per day split into 2–3 sprays over a 14–21 day course, mirroring Russian clinical practice, followed by a 1–3 week washout.

The published Russian clinical trials used the intranasal route. The subcutaneous microgram figures and the 4-on/4-off structure are a community construction; no injectable Selank trial was identified in the sources reviewed. Spray delivery varies by product, so any intranasal total should be calculated from the specific bottle's labeled mcg-per-spray value rather than assumed.

Neutral research-material planning only. This does not establish an appropriate amount or route.

Routes and amounts are not interchangeable unless a verified study explicitly establishes a conversion.

Published study values describe those studies. Community-reported values are not validated dosing recommendations.

Concentration: 2.5 mg/mL

1. 1.Confirm the exact quantity printed on the vial.
2. 2.Choose and record the bacteriostatic water volume; 10 mg into 3 mL gives about 3.33 mg/mL.
3. 3.Clean the stopper with an alcohol swab.
4. 4.Add the liquid slowly down the vial wall.
5. 5.Swirl gently until clear; never shake.
6. 6.Inspect for cloudiness, color or particles and discard anything that is not clear.
7. 7.Label the vial with the concentration and the preparation date.
8. 8.Refrigerate the prepared vial and use only the calculated concentration for arithmetic. This reconstitution guidance does not apply to premixed intranasal spray products.

Reconstitution does not establish identity, purity, sterility, stability, or an appropriate amount.

• Zozulya et al. 2008 compared Selank to medazepam in 62 patients with generalized anxiety disorder or neurasthenia, reporting similar anxiolytic effects plus additional antiasthenic and psychostimulant effects, alongside changes in serum enkephalin-degrading activity.
• Seredenin et al. 2014 compared Selank to phenazepam in 60 patients with phobic-anxiety and somatoform disorders, reporting pronounced anxiolytic and mild nootropic effects, with the anxiolytic effect described as persisting about a week after the last dose.
• Seredenin et al. 2015 studied combined Selank-plus-phenazepam treatment in patients with anxiety disorders, reporting reduced benzodiazepine-related side effects (attention/memory impairment, sedation, sexual disturbance) compared with phenazepam alone.
• Uchakina et al. 2008 reported immunomodulatory effects of Selank in patients with anxiety-asthenic disorders, consistent with its tuftsin-derived origin.
• Kolik et al. 2019 reported that Selank protected against ethanol-induced memory impairment in rats by regulating hippocampal and prefrontal BDNF content, an animal finding.
• No Western randomized, placebo-controlled human trial of Selank was identified, and no published human injection (subcutaneous) study was identified.

This is an evidence-gap and precaution list, not an approved prescribing label.